Rhumbline Advisers Takes Position in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Rhumbline Advisers acquired a new position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS – Free Report) during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor purchased 76,472 shares of the biopharmaceutical company’s stock, valued at approximately $136,000. Rhumbline Advisers owned 0.12% of Regulus Therapeutics at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of RGLS. Vanguard Group Inc. grew its holdings in shares of Regulus Therapeutics by 158.4% in the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock worth $2,132,000 after buying an additional 453,784 shares during the period. CVI Holdings LLC purchased a new stake in Regulus Therapeutics in the 1st quarter worth approximately $4,050,000. Bank of New York Mellon Corp purchased a new stake in Regulus Therapeutics in the second quarter valued at about $352,000. Opaleye Management Inc. purchased a new stake in shares of Regulus Therapeutics in the 1st quarter worth $490,000. Finally, RA Capital Management LP purchased a new position in shares of Regulus Therapeutics in the first quarter valued at $18,000,000. 92.38% of shares are owned by institutional investors and hedge funds.

Regulus Therapeutics price performance

Shares of RGLS stock opened at $1.61 on Monday. The company has a 50 day moving average of $1.63 and a two hundred day moving average of $2.05. The stock has a market cap of $105.40 million, a price-to-earnings ratio of -1.10 and a beta of 1.63. Regulus Therapeutics Inc. it has a one year low of $1.08 and a one year high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS – Get Your Free Report ) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) EPS for the quarter, meeting the consensus estimate of ($0.17). Analysts anticipate that Regulus Therapeutics Inc. will record -0.8 earnings per share for the current year.

Analysts on Wall Street are forecasting an increase

Several research analysts have commented on RGLS shares. Oppenheimer reissued an “outperform” rating and issued a $7.00 price objective on shares of Regulus Therapeutics in a research report on Wednesday, August 14th. Canaccord Genuity Group boosted their price objective on Regulus Therapeutics from $11.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, June 25th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Regulus Therapeutics in a report on Friday, August 9th. Finally, StockNews.com raised Regulus Therapeutics to a “sell” rating in a research note on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Moderate Buy” and an average price target of $10.80, according to data from MarketBeat.

Read the latest stock analysis on Regulus Therapeutics

Regulus Therapeutics Profile

(Free report)

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, a next-generation anti-miR oligonucleotide targeting miR-17, which is in phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.

Featured stories

Want to see what other hedge funds own RGLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Regulus Therapeutics Inc. (NASDAQ:RGLS – Free Report).

Receive news and reviews for Regulus Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Regulus Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.